Hepatitis occurs in 5–10% of patients during treatment with ICI as a monotherapy (~2% grade 3) and 25–30% during treatment with a combination of anti-PD(L)-1 and anti-CTLA-4 (~15% grade 3) [19]. This evidence concerns the gene CTLA4 and Hepatitis.